Department of Otolaryngology - Head & Neck Surgery, University of Toronto, Toronto, Ontario, Canada; Institute of Health Policy, Management and Evaluation (IHPME), University of Toronto, Toronto, Ontario, Canada.
Institute of Health Policy, Management and Evaluation (IHPME), University of Toronto, Toronto, Ontario, Canada; Division of Otolaryngology Head & Neck Surgery, Dalhousie University, Halifax, Nova Scotia, Canada.
Oral Oncol. 2021 Dec;123:105595. doi: 10.1016/j.oraloncology.2021.105595. Epub 2021 Nov 11.
Symptom burden is common in head and neck cancer patients though it frequently remains undetected and untreated. The Edmonton Symptom Assessment System - revised version (ESAS-r) is a generic symptom scale deployed in many outpatient settings worldwide. The ESAS-r is meant to improve symptom detection and management. We sought to review the ESAS-r and its psychometric properties in a head and neck oncology population.
Narrative Review.
Over the past 30 years, the ESAS-r has emerged as one of the most used symptom scales for cancer patients. Its psychometric properties in a heterogenous cancer population are well supported, proving to be reliable and valid in a variety of settings. The linking of ESAS-r scores with Ontario administrative health data has led to a detailed assessment of validity in head and neck cancer. The ESAS-r can discriminate between high and low levels of symptom burden and is responsive to change over time in this patient population. ESAS-r scores have also been shown to be a strong predictor of future emergency department use and unplanned hospitalization in head and neck cancer patients.
The ESAS-r is reliable and valid in the head and neck cancer population and may serve as a useful clinical endpoint in research studies.
尽管症状负担在头颈部癌症患者中很常见，但通常未被发现和治疗。埃德蒙顿症状评估系统-修订版（ESAS-r）是一种在全球许多门诊环境中使用的通用症状量表。ESAS-r 旨在改善症状的检测和管理。我们旨在审查头颈部肿瘤患者中的 ESAS-r 及其心理测量特性。
叙述性评论。
在过去的 30 年中，ESAS-r 已成为癌症患者最常用的症状量表之一。它在异质癌症人群中的心理测量特性得到了很好的支持，在各种环境中被证明是可靠和有效的。将 ESAS-r 评分与安大略省行政健康数据相关联，对头颈部癌症的有效性进行了详细评估。ESAS-r 可区分高和低水平的症状负担，并对头颈部癌症患者随时间的变化具有反应性。ESAS-r 评分也被证明是头颈部癌症患者未来急诊使用和非计划住院的强有力预测指标。
ESAS-r 在头颈部癌症患者中可靠且有效，可作为研究中的有用临床终点。
